Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals.
Authors:
- E L CareyECE L Carey
- H J DuffHDH J Duff
- D M RodenDRD M Roden
- R K PrimmRPR K Primm
- G R WilkinsonGWG R Wilkinson
- T WangTWT Wang
- J A OatesJOJ A Oates
- R L WoosleyRWR L Woosley
Open Access
- 1 February 1984
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 73 (2) , 539-547
Abstract
To assess the relative contributions of encainide and its putatively active metabolites, O-demethyl encainide (ODE) and 3 methoxy-O-demethyl encainide (3MODE), to the drug's pharmacologic effects, we compared intravenous infusions and sustained oral therapy in two phenotypically distinct groups of patients, extensive and poor metabolizers of encainide. Unlike poor metabolizers, extensive metabolizers had appreciable quantities of both metabolites detectable in plasma and had fourfold shorter elimination half-lives for encainide. By quantitating electrocardiogram intervals, arrhythmia frequency, and plasma concentrations, we found that, in poor metabolizers, arrhythmia suppression and ventricular complex (QRS) prolongation were correlated positively with encainide concentrations (r greater than or equal to 0.570, P less than 0.014). In these two subjects, antiarrhythmic concentrations of encainide (greater than 265 ng/ml) were at least fivefold higher than those sustained in the six extensive metabolizers during steady state oral therapy. In extensive metabolizers, encainide concentrations were uncorrelated with effects. Arrhythmia suppression and QRS prolongation in extensive metabolizers correlated best with ODE (r greater than or equal to 0.816, P less than 0.001); QTc change correlated positively with both 3MODE and ODE. Arrhythmia suppression paralleled QRS prolongation; the relationship between them appeared similar in both phenotypic groups. In most patients, extensive metabolizers, encainide effects during oral therapy are mediated by metabolites, probably ODE.Keywords
This publication has 26 references indexed in Scilit:
- Response to Encainide of Refractory Ventricular TachycardiaJournal of Cardiovascular Pharmacology, 1982
- Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylationClinical Pharmacology & Therapeutics, 1981
- Antiarrhythmic efficacy of encainide in patients with refractory recurrent ventricular tachycardia.Circulation, 1981
- Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: Comparison with procainamideThe American Journal of Cardiology, 1980
- Some statistical methods useful in circulation research.Circulation Research, 1980
- Procainamide delivery to ischemic canine myocardium following rapid intravenous administration.Circulation Research, 1980
- Total Suppression of Ventricular Arrhythmias by EncainideNew England Journal of Medicine, 1980
- Clinical electrophysiologic effects of encainide, a newly developed antiarrhythmic agentThe American Journal of Cardiology, 1979
- Clinical experience of encainide (MJ 9067): A new anti-arrhythmic drugEuropean Journal of Clinical Pharmacology, 1979
- Polymorphism of carbon oxidation of drugs and clinical implications.BMJ, 1978